Volume 90, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



is one of the most common human parasitic infections in the United States, as well as the most prevalent non-viral sexually transmitted infection. However, it has long received much less consideration than other parasitic and sexually transmitted diseases. Much of this inattention can be attributed to a poor understanding of the public health impact of trichomoniasis. Increasing recognition of the sequelae of infection, including increased risk of infection with human immunodeficiency virus and adverse outcomes of pregnancy, has led to increased interest in . Recent innovations include development of diagnostic tests that could improve detection of the parasite. A number of important questions, such as the epidemiology among men and women, the true public health burden of symptomatic and asymptomatic infections, and whether current treatments will be adequate to reduce the substantial health disparities and costs associated with trichomoniasis, need consideration to remedy neglect of this important disease.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

Loading full text...

Full text loading...



  1. World Health Organization, 2011. Prevalence and Incidence of Selected Sexually Transmitted Infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: Methods and Results Used by WHO to Generate 2005 Estimates. Available at: http://whqlibdoc.who.int/publications/2011/9789241502450_eng.pdf. Accessed February 8, 2013.
  2. Sutton M, Sternberg M, Koumans EH, McQuillan G, Berman S, Markowitz L, , 2007. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004. Clin Infect Dis 45: 13191326.[Crossref]
  3. Van der Pol B, , 2007. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 44: 2325.[Crossref]
  4. Satterwhite CL, Torrone E, Meites E, Dunne E, Mahajan R, Ocfemia MC, Su J, Xu F, Weinstock H, , 2013. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 40: 187193.[Crossref]
  5. Seña AC, Miller WC, Hobbs MM, Schwebke JR, Leone PA, Swygard H, Atashili J, Cohen M, , 2007. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 44: 1322.[Crossref]
  6. Wølner-Hanssen P, Krieger JN, Stevens CE, Kiviat NB, Koutsky L, Critchlow C, DeRouen T, Hillier S, Holmes KK, , 1989. Clinical manifestations of vaginal trichomoniasis. JAMA 261: 571576.[Crossref]
  7. Swygard H, Se˜na AC, Hobbs MM, Cohen MS, , 2003. Trichomoniasis: clinical manifestations, diagnosis and management. Sex Transm Infect 80: 9195.[Crossref]
  8. Peterman TA, Tian LH, Metcalf CA, Satterwhite CL, Malotte CK, DeAugustine N, Paul SM, Cross H, Rietmeijer CA, Douglas JM, Jr RESPECT-2 Study Group, , 2006. High incidence of new sexually transmitted infections in the year following a sexually transmitted infection: a case for rescreening. Ann Intern Med 145: 564572.[Crossref]
  9. Minkoff H, Grunebaum AN, Schwarz RH, Feldman J, Cummings M, Crombleholme W, Clark L, Pringle G, McCormack WM, , 1984. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 150: 965972.[Crossref]
  10. Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, Eschenbach DA, Edelman R, Carey JC, Regan JA, Krohn MA, Klebanoff MA, Rao AV, Rhoads GG, the Vaginal Infections and Prematurity Study Group, , 1997. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 24: 353360.[Crossref]
  11. Mann JR, McDermott S, Gill T, , 2010. Sexually transmitted infection is associated with increased risk of preterm birth in South Carolina women insured by Medicaid. J Matern Fetal Neonatal Med 23: 563568.[Crossref]
  12. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW, , 2002. Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 34: 519522.[Crossref]
  13. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, Goeman J, Behets F, Batter V, Alary M, Heyward WL, Ryder RW, Piot P, , 1993. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 7: 95102.[Crossref]
  14. Laga M, Alary M, Nzila N, Monoka AT, Tuliza M, Behets F, Goeman J, St. Louis M, Piot P, , 1994. Condom promotion, sexually transmitted diseases treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 34: 246248.[Crossref]
  15. McClelland RS, Sangaré L, Hassan WM, Lavreys L, Mandaliya K, Kiarie J, Ndinya-Achola J, Jaoko W, Baeten JM, , 2007. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 195: 698702.[Crossref]
  16. Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen P-L, van de Wijgert J, Mmiro F, Mugerwa R, Chipato T, Morrison CS, , 2008. Trichomonas vaginalis infection and human imunodeficiency virus acquisition in African women. J Infect Dis 197: 548554.[Crossref]
  17. Hughes JP, Baeten JM, Lingappa JR, Magaret AS, Wald A, de Bruyn G, Kiarie J, Inambao M, Kilembe W, Farquhar C, Celum C, the Partners in Prevention HSV/HIV Transmission Study Team, , 2012. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis 205: 358365.[Crossref]
  18. Wang CC, McClelland RS, Reilly M, Overbaugh J, Emery SR, Mandaliya K, Chohan B, Ndinya-Achola J, Bwayo J, Kreiss JK, , 2001. The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis 183: 10171022.[Crossref]
  19. Kissinger P, Amedee A, Clark RA, Dumestre J, Theall KP, Myers L, Hagensee ME, Farley TA, Martin DH, , 2009. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 36: 1116.[Crossref]
  20. Homans J, Christensen S, Stiller T, Wang C-H, Mack W, Anastos K, Minkoff H, Young M, Greenblatt R, Cohen M, Strickler H, Karim R, Spencer LY, Operskalski E, Frederick T, Kovacs A, , 2012. Permissive and protective factors associated with presence, level, and longitudinal pattern of cervicovaginal HIV shedding. J Acquir Immune Defic Syndr 60: 99110.[Crossref]
  21. Allsworth JE, Ratner JA, Peipert JF, , 2009. Trichomoniasis and other sexually transmitted infections: results from the 2001–2004 national health and nutrition examination surveys. Sex Transm Dis 36: 738744.[Crossref]
  22. Weston TE, Nicol CS, , 1963. Natural history of trichomonal infection in males. Br J Vener Dis 39: 251257.
  23. Krieger JN, , 1993. Trichomoniasis in men: old issues and new data. Sex Transm Dis 22: 8396.[Crossref]
  24. Hobbs MM, Kazember P, Reed AW, Miller WC, Nkata E, Zimba D, Daly CC, Chakraborty H, Cohen MS, Hoffman I, , 1999. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 26: 381387.[Crossref]
  25. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA, , 2009. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: physicians' health study. J Natl Cancer Inst 101: 14061411.[Crossref]
  26. Sutcliffe S, Neace C, Magnuson NS, Reeves R, Alderete JF, , 2012. Trichomoniasis, a common curable STI, and prostate carcinogenesis: a proposed molecular mechanism. PLoS Pathog 8: e1002801.[Crossref]
  27. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, Hobbs MM, , 2007. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 45: 194198.[Crossref]
  28. Nye MB, Schwebke JR, Body BA, , 2009. Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 200: 188 e11e7.
  29. Stoner KA, Rabe LK, Meyn LA, Hillier SL, , 2013. Survival of Trichomonas vaginalis in wet preparation and on wet mount. Sex Transm Infect 89: 485488.[Crossref]
  30. Chapin K, Sndrea S, , 2011. APTIMA® Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens. Expert Rev Mol Diagn 11: 679688.[Crossref]
  31. Huppert JS, Mortensen JE, Reed JL, Kahn JA, Rich KD, Miller WC, Hobbs MM, , 2007. Rapid antigen testing compares favorably with transcription-mediated amplification assay for the detection of Trichomonas vaginalis in young women. Clin Infect Dis 45: 194198.[Crossref]
  32. Jones HE, Lippman SA, Caiaffa-Filho HH, Young T, van de Wijgert JH, , 2013. Perfomance of a rapid self-test for detection of Trichomonas vaginalis in South Africa and Brazil. J Clin Microbiol 51: 10371039.[Crossref]
  33. Pearce DM, Styles DN, Hardick JP, Gaydos CA, , 2013. A new rapid molecular point-of-care assay for Trichomonas vaginalis: preliminary performance data. Sex Transm Infect 89: 495497.[Crossref]
  34. Workowski KA, Berman SM, Centers for Disease Control and Prevention, , 2010. Sexually Transmitted Diseases Treatment Guidelines, 2010. Clin Infect Dis 53 (Suppl 3): S59S63.
  35. Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, Kerani RP, Mettenbrink CJ, Pathela P, Schwebke JR, Secor WE, Workowski KA, Davis D, Braxton J, Weinstock HS, , 2012. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 18: 939943.[Crossref]
  36. Kissinger P, Secor WE, Leichliter JS, Clark RA, Schmidt N, Curtin E, Martin DH, , 2008. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 46: 994999.[Crossref]
  37. Helms DJ, Mosure DJ, Secor WE, Workowski KA, , 2008. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 98: 370 e1e7.
  38. Asensio T, Dávila I, Moreno E, Laffond E, Macías E, Ruiz A, Lorente F, , 2008. Anaphylaxis due to metronidazole with positive skin prick test. J Investig Allergol Clin Immunol 18: 136142.
  39. Piskin G, Mekkes JR, , 2006. Stevens-Johnson syndrome from metronidazole. Contact Dermat 55: 192193.[Crossref]
  40. Miller WC, Swygard H, Hobbs MM, Ford CA, Handcock MS, Morris M, Schmitz JL, Cohen MS, Harris KM, Udry JR, , 2005. The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis 32: 593598.[Crossref]
  41. Munson E, Kramme T, Napierala M, Munson KL, Miller C, Hryciuk JE, , 2012. Female epidemiology of transcription-mediated amplification-based Trichomonas vaginalis detection in a metropolitan setting with a high prevalence of sexually transmitted infection. J Clin Microbiol 50: 39273931.[Crossref]
  42. Munson KL, Napierala M, Munson E, Schell RF, Kramme T, Miller C, Hryciuk JE, , 2013. Screening of male patients for Trichomonas vaginalis with transcription-mediated amplification in a community with a high prevalence of sexually transmitted infection. J Clin Microbiol 51: 101104.[Crossref]
  43. Hoots BE, Peterman TA, Torrone EA, Weinstock H, Meites E, Bolan GA, , 2013. A trich-y question: should Trichomonas vaginalis infection be reportable? Sex Transm Dis 40: 113116.[Crossref]
  44. Owusu-Edusei K, Jr Chesson HW, Gift TL, Tao G, Mahajan R, Ocfemia MC, Kent CK, , 2013. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 40: 197201.[Crossref]
  45. Quinlivan EB, Patel SN, Grodensky CA, Colin CE, Tien H-C, Hobbs MM, , 2012. Modeling the impact of Trichomonas vaginalis infection on HIV transmission in HIV-infected individuals in medical care. Sex Transm Dis 39: 671677.[Crossref]
  46. Chesson HW, Blandford JM, Pinkerton SD, , 2004. Estimates of the annual number and cost of new HIV infections among women attributable to trichomoniasis in the United States. Sex Transm Dis 31: 547551.[Crossref]
  47. Gaydos CA, Hsieh Y-H, Barnes M, Quinn N, Agreda P, Jett-Goheen M, Whittle P, Hogan T, , 2011. Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment. Sex Transm Dis 38: 828832.[Crossref]
  48. Gaydos CA, Barnes MR, Quinn N, Jett-Goheen M, Hsieh Y-H, , 2013. Trichomonas vaginalis infection in men who submit self-collected penile swabs after internet recruitment. Sex Transm Infect 89: 504508.[Crossref]
  49. Lustig G, Ryan CM, Secor WE, Johnson PJ, , 2013. Trichomonas vaginalis contact dependent cytolysis of epithelial cells. Infect Immun 81: 14111419.[Crossref]
  50. Mann JR, McDermott S, Barnes TL, Hardin J, Bao H, Zhou L, , 2009. Trichomoniasis in pregnancy and mental retardation in children. Ann Epidemiol 19: 891899.[Crossref]
  51. Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, Ernest JM, Heine RP, Wapner RJ, Trout W, Moawad A, Leveno KJ, Miodovnik M, Sibai BM, Van Dorsten JP, Dombrowski MP, O'Sullivan MJ, Varner M, Langer O, McNellis D, Roberts JM, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units; , 2001. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 345: 487493.[Crossref]
  52. Helms DJ, Mosure DJ, Metcalf CA, Douglas JM, Malotte CK, Paul SM, Peterman TA, , 2008. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis 35: 484488.[Crossref]
  53. Peterman TA, Tian LH, Metcalf CA, Malotte K, Paul SM, Douglas JM, for the RESPECT-2 Study Group, , 2009. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 48: 259260.[Crossref]
  54. Gatski M, Kissinger P, , 2010. Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women. Clin Infect Dis 21: 114115.[Crossref]
  55. Bosserman EA, Helms DJ, Mosure DJ, Secor WE, Workowski KA, , 2011. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure. Sex Transm Dis 38: 983987.[Crossref]
  56. Hobbs MM, Lapple DM, Lawing LF, Schwebke JR, Cohen MS, Swygard H, Atashili J, Leone PA, Miller WC, Seña AC, , 2006. Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol 44: 39943999.[Crossref]
  57. Price MA, Stewart SR, Miller WC, Behets F, Dow WH, Martinson FEA, Chilongozi D, Cohen MS, , 2006. The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr 43: 202209.[Crossref]
  58. Carlton JM, Hirt RP, Silva JC, Delcher AL, Schatz M, Zhao Q, Wortman JR, Bidwell SL, Alsmark UC, Besteiro S, Sicheritz-Ponten T, Noel CJ, Dacks JB, Foster PG, Simillion C, Van de Peer Y, Miranda-Saavedra D, Barton GJ, Westrop GD, Müller S, Dessi D, Fiori PL, Ren Q, Paulsen I, Zhang H, Bastida-Corcuera FD, Simoes-Barbosa A, Brown MT, Hayes RD, Mukherjee M, Okumura CY, Schneider R, Smith AJ, Vanacova S, Villalvazo M, Haas BJ, Pertea M, Feldblyum TV, Utterback TR, Shu CL, Osoegawa K, de Jong PJ, Hrdy I, Horvathova L, Zubacova Z, Dolezal P, Malik SB, Logsdon JM, Jr Henze K, Gupta A, Wang CC, Dunne RL, Upcroft JA, Upcroft P, White O, Salzberg SL, Tang P, Chiu CH, Lee YS, Embley TM, Coombs GH, Mottram JC, Tachezy J, Fraser-Liggett CM, Johnson PJ, , 2007. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis . Science 315: 207212.[Crossref]
  59. Conrad MD, Gorman AW, Schillinger JA, Fiori PL, Arroyo R, Malla N, Dubey ML, Gonzalez J, Blank S, Secor WE, Carlton JM, , 2012. Extensive genetic diversity, unique population structure and evidence of genetic exchange in the sexually transmitted parasite Trichomonas vaginalis . PLoS Negl Trop Dis 6: e1573.[Crossref]
  60. Hirt RP, , 2013. Trichomonas vaginalis virulence factors: an integrative overview. Sex Transm Infect 89: 439443.[Crossref]
  61. Meade JC, Carlton JM, , 2013. Genetic diversity in Trichomonas vaginalis . Sex Transm Infect 89: 444448.[Crossref]
  62. Goodhew EB, Secor WE, , 2013. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 89: 479484.[Crossref]
  63. Helms DJ, Mosure DJ, Secor WE, Workowski KA, , 2008. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 198: 370 e1e7.
  64. Muzny C, Barnes A, Mena L, , 2012. Symptomatic Trichomonas vaginalis infections in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 9: 389391.[Crossref]
  65. Ratzan JJ, , 1969. Monilial and trichomonal vaginitis. Topical treatment with povidone-iodine preparations. Calif Med 110: 2427.
  66. Waters LJ, Dave SS, Deayton JR, French PD, , 2005. Recalcitrant Trichomonas vaginalis infection: a case series. Int J STD AIDS 16: 505509.[Crossref]
  • Received : 10 Dec 2013
  • Accepted : 16 Feb 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error